CONFERENCE UPDATE: CROI 2022

Outcomes of NADIA trial at 96 weeks

INFECTIOUS DISEASE
30 Mar 2022

Get access to our exclusive articles.
Related Articles

Twice yearly lenacapavir demonstrates remarkable efficacy in HIV prevention: Results from the phase 3 PURPOSE 1 trial

Despite the availability of once-daily oral emtricitabine–tenofovir disoproxil fumarate (F/TDF) as a highly effective pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) prevention, significant unmet needs remain.1,2 Many individuals, particularly adolescent girls and young women,
INFECTIOUS DISEASE
19 Sep 2024

Long-term evaluation of TAF vs. TDF antiviral prophylaxis in post-OLT patients with CHB

A recent randomized, phase 2 study by Gane, E.J. and colleagues presented at the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2021 demonstrated the high long-term efficacy and safety of tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF) antiviral prophylaxis in post-orthotopic liver transplant (OLT) patients with chronic hepatitis B virus (HBV) infection.1 The renal- and bone-protecting effects on patients with TAF were shown to be more profound than those with TDF.1
31 Mar 2022

HIV RNA assay screening reduces INSTI resistance risk in CAB-LA for PrEP

In the 2022 Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Susan Eshleman from the School of Medicine of John Hopkins University, Baltimore of the United States (US), presented a study on human immunodeficiency virus (HIV) screening using ribonucleic acid (RNA) assays in patient
INFECTIOUS DISEASE
30 Mar 2022

5-year outcomes of B/F/TAF in treatment-naïve adults

Bictegravir (B; BIC), emtricitabine (F; FTC), and tenofovir alafenamide (TAF) or B/F/TAF is a single-tablet coformulation that is recommended for people living with human immunodeficiency virus (HIV).1 It can be taken once daily without food restrictions, and has a high barrier to resistance with a favorable drug-drug interaction profile.1

This presentation reported the 5-year treatment outcomes of B/F/TAF in treatment-naïve adults.  There were 2 randomized, double-blind phase 3 studies of B/F/TAF in treatment-naïve adults, namely study 1489 [B/F/TAF vs. dolutegravir/abacavir/lamivudine (DTG/ABC/3TC)] and study 1490 (B/F/TAF vs. DTG+F/TAF).1 After 144 weeks of blinded treatments, subjects were offered a continuation of B/F/TAF for 96 weeks as part of an open-label extension study.1 Efficacy was assessed as proportion with HIV-1 (ribonucleic acid) RNA <50 copies/mL at each visit after B/F/TAF using missing=excluded (M=E) analysis, safety and laboratory results.1 

INFECTIOUS DISEASE
30 Mar 2022

Metabolic and renal side effects of monthly ISL for HIV PrEP

Currently approved human immunodeficiency virus-1 (HIV-1) pre-exposure prophylaxis (PrEP) regimens have been associated with long-term adverse events (AEs) including weight change, loss of bone mineral density, and changes in renal function.1 

INFECTIOUS DISEASE
30 Mar 2022

Are we closer to a cure for HIV?

Thirty months following treatment interruption, a patient known as the "London patient" has continued to remain in sustained remission of human immunodeficiency virus (HIV) status.1

INFECTIOUS DISEASE
29 Apr 2020

Further efforts are required to end HIV epidemics worldwide

Advances in the HIV prevention and treatment have increased the likelihood of eliminating the HIV epidemic, although changes in the disease management guidelines have yet to be implemented. Indeed, the HIV experts always emphasize the importance of accessible HIV testing campaigns,

INFECTIOUS DISEASE
31 Oct 2019

Frontiers in the management and prevention of infectious diseases

The estimated number of people living with human immunodeficiency virus (HIV) infection was 36.9 million in 2014.1 An estimated 15.2% of people living with HIV are located in the Asia-Pacific region.2

DIABETES & ENDOCRINOLOGY
30 Aug 2019